FORMULATION AND EVALUATION OF NIOSOMAL GEL CONTAINING TAZAROTENE FOR THE TREATMENT OF ACNE AND PSORIASIS

##plugins.themes.academic_pro.article.sidebar##

Published Jul 10, 2022
Download
PDF
Statistic

Downloads

Download data is not yet available.
Vol. 5 No. 04 (2022): International Journal of Medical Science in Clinical Research and Review

##plugins.themes.academic_pro.article.main##

1Mr. Ravi malviya, 2Miss Deepshikha gunwan, 3Dr. C.K. Tyagi,4Dr. Sunil Shah, 5Mr. Abdul Wajid Ali
1. Research Scholar, College of Pharmacy, SSSUTMS Sehore (M.P.) 2. Assistant Professor College of Pharmacy, SSSUTMS Sehore (M.P.) 3. Dean College of Pharmacy, SSSUTMS Sehore (M.P.) 4. Professor, College of Pharmacy, SSSUTMS Sehore (M.P.) 5. Assistant Professor College of Pharmacy, SSSUTMS Sehore (M.P.)

Abstract

Psoriasis is a chronic inflammatory skin disorder that may drastically affect the quality of life of an affected person. Different treatments are available for psoriasis and among this topical therapy are most commonly used in majority of patients. Tazarotene is a prescription topical retinoid sold as a cream or gel. This medication is approved for treatment of psoriasis, acne, and sun damaged skin (photodamage). This compound belongs to the class of organic compounds known as retinoids. In Present study aimed to develop niosomal gel for the treatment of acne and psoriasis. The release of the drug in the deep layers of the skin and its transdermal absorption could then be the result of a fusion of niosomes, with skin lipids and drug release at various points along the penetration pathway. It can be concluded that a gel formulation containing niosomes loaded with Tazarotene showed prolonged action and it can be developed successfully to improve the dermal infections.

##plugins.themes.academic_pro.article.details##

How to Cite
5Mr. Abdul Wajid Ali, 1Mr. R. malviya, 2Miss D. gunwan, 3Dr. C. T. S. S. (2022). FORMULATION AND EVALUATION OF NIOSOMAL GEL CONTAINING TAZAROTENE FOR THE TREATMENT OF ACNE AND PSORIASIS. International Journal of Medical Science in Clinical Research and Review, 5(04), Page: 155–171. Retrieved from https://ijmscrr.in/index.php/ijmscrr/article/view/203

References

    1. Saraswat A, Agarwal R, Katare OP, Kaur I, Kumar B. A randomized, double blind, vehicle controlled study of a novel liposomal dithranol formulation in psoriasis. J Dermatol Treatment, 2007; 18: 40-45.
    2. Voorhees AV, Feldman SR, Koo JYM, Lebwohl MG,Menter A. The psoriasis and psoriatic arthritis pocket guide: Treatment options and patient management. 3rd ed, publ. National Psoriasis Foundation, Portland,USA, 2009.
    3. Cevc G, Gebauer D. Hydration-Driven Transport of Deformable Lipid Vesicles through Fine Pores and the Skin Barrier. Biophysical Journal, 2003; 84: 1010–1024.
    4. Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev, 2004; 56: 675– 711.
    5. Lopes LB, Speretta FF, Bentley MV. Enhancement of skin penetration of vitamin K using monoolein-based liquid crystalline systems. Eur J Pharm Sci, 2007; 32:209–215.
    6. Benson HAE. Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv 2005; 2:23-33.
    7. Vyas SP, Khar RK. Controlled drug delivery system.1st ed: Vallabh prakashan. 2005. p. 417-426.
    8. Khan, A.; Sharma, P.K.; Visht, S. & Malviya, R., (2011). Niosomes as colloidal drug delivery system: A review. Journal of Chronotherapy and Drug Delivery, Vol. 2, No. 1, pp. 15-21
    9. Azeem, A.; Anwer, M.K. & Talegaonkar, S., (2009). Niosomes in sustained and targeted drug delivery: some recent advances. J Drug Target, Vol. 17, No. 9, pp. 671-689, ISSN: 1061- 186X.
    10. Handjani-Vila, R.M.; Ribier, A.; Rondot, B. & Vanlerberghe, G., (1979). Dispersions of lamellar phases of non-ionic lipids in cosmetic products. Int J Cosmetic Sci, Vol. 1, pp. 303-314.
    11. Perrett, S.; Golding, M. & Williams, W.P., (1991). A simple method for the preparation of liposomes for pharmaceutical application and characterization of liposomes. J Pharm Pharmacol, Vol. 43, pp. 154-161, ISSN: 2042-7158.
    12. Gopinath, D.; Ravi, D.; Rao, B.R.; Apte, S.S.; Renuka, D. & Rambhau, D., (2004). Ascorbyl palmitate vesicles (Aspasomes): formation, characterization and applications. Int J Pharm, Vol. 271, No. 1-2, pp. 95-113, ISSN: 0378-5173.
    13. Yoshida, H.; Lehr, C.M.; Kok, W.; Junginger, H.E.; Verhoef, J.C. & Bouwstra, J.A., (1992). Niosomes for oral delivery of peptide drugs. J Control Release, Vol. 21, No. 1-3, pp. 145- 153, ISSN: 0168-3659.
    14. Yoshioka, T.; Sternberg, M.; Moody, M. & Florence, A.T., (1992). Niosomes from Span surfactants: Relations between structure and form. J Pharm Pharmacol, Vol. 44, pp. 1044- 1044, ISSN: 0022-3573.
    15. Cevc, G., (1996). Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst, Vol. 13, No. 3-4, pp. 257, ISSN: 0743-4863.
    16. Cevc, G.; Blume, G.; Schätzlein, A.; Gebauer, D. & Paul, A., (1996). The skin: a pathway for systemic treatment with patches and lipid-based agent carriers. Adv Drug Deliv Rev, Vol. 18, No. 3, pp. 349-378, ISSN: 0169- 409X.
    17. Agarwal, R.; Katare, O.P. & Vyas, S.P., (2001). Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm, Vol. 228, No. 1, pp. 43-52, ISSN: 0378-5173.
    18. Baillie, A.J.; Coombs, G.H.; Dolan, T.F. & Laurie, J., (1986). Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharm Pharmacol, Vol. 38, No. 7, pp. 502- 505, ISSN: 0022-3573
    19. Abdelkader, H.; Wu, Z.; Al-Kassas, R. & Alany, R.G., (2012). Niosomes and discomes for ocular delivery of naltrexone hydrochloride: morphological, rheological, spreading properties and photo-protective effects. Int J Pharm, Vol. 433, No. 1-2, pp. 142-148, ISSN: 0378-5173.
    20. Ruckmani, K.; Jayakar, B. & Ghosal, S.K., (2000). Nonionic surfactant vesicles (niosomes) of cytarabine hydrochloride for effective treatment of leukemias: Encapsulation, storage, and in vitro release. Drug Dev Ind Pharm, Vol. 26, No. 2, pp. 217-222, ISSN: 0363- 9045.
    21. Pardakhty, A.; Varshosaz, J. & Roulholamini, A., (2007). In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm, Vol. 328, pp. 130-141, ISSN: 0378-5173.
    22. Jain, C.P.; Vyas, S.P. & Dixit, V.K., (2006). Niosomal system for delivery of rifampicin to lymphatics. Indian J Pharm Sci, Vol. 68, No. 5, pp. 575, ISSN: 0250-474X.
    23. Sahin, N.O. Niosomes as nanocarrier systems. Nanomaterials and nanosystems for biomedical applications2007. p. 67-81.
    24. Ogiso, T.; Niinaka, N. & Iwaki, M., (1996). Mechanism for enhancement effect of lipid disperse system on percutaneous absorption. J Pharm Sci, Vol. 85, pp. 57-64, ISSN: 1520- 6017.
    25. Fang, J.Y.; Hong, C.T.; Chiu, W.T. & Wang, Y.Y., (2001). Effect of liposomes and niosomes on skin permeation of enoxacin. Int J Pharm, Vol. 219, No. 1-2, pp. 61-72, ISSN: 0378- 5173.
    26. Javadzadeh, Y.; Shokri, J.; Hallaj-Nezhadi, S.; Hamishehkar, H. & Nokhodchi, A., (2010). Enhancement of percutaneous absorption of Finasteride by cosolvents, cosurfactant and surfactants. Pharm Dev Technol, Vol. 15, No. 6, pp. 619-625, ISSN: 1083-7450.
    27. Hofland, H.; Bowuwstra, J.A.; Ponec, M. Boddé, H.E.; Spies, F.; Coos Verhoef, J.; Junginger H.E., (1991). Interactions of non-ionic surfactant vesicles with cultured keratinocytes and human skin in vitro: a survey of toxicological aspects and ultrastructural changes in stratum corneum. J Control Release, Vol. 16, No. 1, pp. 155-167, ISSN: 0168-3659.
    28. E. Nagarajan, P. Shanmugasundaram, V. Ravichandiran, A. Vijayalakshmi, B. Senthilnatha, K. Masilamani, Development and Evaluation of Chitosan Based Polymeric Nanoparticles of an Antiulcer Drug Lansoprazole, Journal of Applied Pharmaceutical Science Vol. 5 (04), pp. 020-025, April, 2015.
    29. Partha Saha, Amit K Goyal and Goutam Rath, Formulation and Evaluation of Chitosan-Based Ampicillin Trihydrate Nanoparticles, Tropical Journal of Pharmaceutical Research October 2010; 9 (5): 483-488.
    30. D. Karthikeyan, M. Srinivas, C. Santhosh Kumar, Formulation and Evaluation of Stavudine Nanoparticles, International Journal of Novel Trends in Pharmaceutical Sciences Vol 3, No. 1, FEB 2013, pp- 24-32.
    31. J. Adlin Jino Nesalin , A. Anton Smith, Preparation and evaluation of chitosan nanoparticles containing zidovudine, Asian Journal of Pharmaceutical Sciences 2012, 7 (1): 80-84.
    32. Gupta Dilip Kumar, Razdan B.K., Bajpai Meenakshi, Formulation and Evaluation of Nanoparticles Containing Artemisinin HCL, Int. J. Res. Dev. Pharm. L. Sci. February -March, 2014, 3(2), 925-934.
    33. Priyanka Patil and Manisha Bhoskar, Optimization and Evaluation of Spray Dried Chitosan Nanoparticles Containing Doxorubicin, Int J Curr Pharm Res, Vol 6, Issue 1, (2014) 7-15.
    34. okkalingam Arumugam Dhanaraj,Selvadurai Muralidharan, Kumaraswamy Santhi, Amanda Lim Sze Hui, Cheong Jia Wen, Hoh Chew Teng, Targeted drug delivery system- Formulation and evaluation of chitosan nanospheres containing Doxorubicin hydrochloride, International Journal of Drug Delivery 6 (2014) 186-193.
    35. Afifa Bathool, Gowda D. Vishakante, Mohammed S. Khan, H. G. Shivakumar, Development and characterization of atorvastatin calcium loaded chitosan nanoparticles for sustain drug delivery, Adv. Mat. Lett. 2012, 3(6), 466-470.
    36. J. B. Varuna Kumara, and Basavaraj Madhusudhan, Formulation and Evaluation of Atorvastatin Calcium Loaded Chitosan Nanoparticles, Int J Pharm Bio Sci 2015 July, 6(3), pp 50 – 58.